vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $177.1M, roughly 1.0× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs -0.7%, a 33.6% gap on every dollar of revenue. On growth, GCM Grosvenor Inc. posted the faster year-over-year revenue change (7.2% vs 0.7%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $21.3M). Over the past eight quarters, GCM Grosvenor Inc.'s revenue compounded faster (27.5% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
AVNS vs GCMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $177.1M |
| Net Profit | $-1.3M | $58.2M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 30.9% |
| Net Margin | -0.7% | 32.8% |
| Revenue YoY | 0.7% | 7.2% |
| Net Profit YoY | 99.7% | 149.2% |
| EPS (diluted) | $-0.02 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $177.1M | ||
| Q3 25 | $177.8M | $135.0M | ||
| Q2 25 | $175.0M | $119.7M | ||
| Q1 25 | $167.5M | $125.8M | ||
| Q4 24 | $179.6M | $165.3M | ||
| Q3 24 | $170.4M | $122.9M | ||
| Q2 24 | $171.7M | $117.0M | ||
| Q1 24 | $166.1M | $108.9M |
| Q4 25 | $-1.3M | $58.2M | ||
| Q3 25 | $-1.4M | $10.5M | ||
| Q2 25 | $-76.8M | $15.4M | ||
| Q1 25 | $6.6M | $463.0K | ||
| Q4 24 | $-397.3M | $7.6M | ||
| Q3 24 | $4.3M | $4.2M | ||
| Q2 24 | $1.8M | $4.8M | ||
| Q1 24 | $-900.0K | $2.1M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 30.9% | ||
| Q3 25 | 0.1% | 32.7% | ||
| Q2 25 | -42.6% | 16.1% | ||
| Q1 25 | 6.1% | 12.2% | ||
| Q4 24 | -233.0% | 26.4% | ||
| Q3 24 | 7.0% | 20.3% | ||
| Q2 24 | 3.7% | 17.8% | ||
| Q1 24 | 2.4% | -14.7% |
| Q4 25 | -0.7% | 32.8% | ||
| Q3 25 | -0.8% | 7.8% | ||
| Q2 25 | -43.9% | 12.9% | ||
| Q1 25 | 3.9% | 0.4% | ||
| Q4 24 | -221.2% | 4.6% | ||
| Q3 24 | 2.5% | 3.4% | ||
| Q2 24 | 1.0% | 4.1% | ||
| Q1 24 | -0.5% | 2.0% |
| Q4 25 | $-0.02 | $0.23 | ||
| Q3 25 | $-0.03 | $0.16 | ||
| Q2 25 | $-1.66 | $0.05 | ||
| Q1 25 | $0.14 | $-0.02 | ||
| Q4 24 | $-8.64 | $0.09 | ||
| Q3 24 | $0.09 | $0.03 | ||
| Q2 24 | $0.04 | $0.04 | ||
| Q1 24 | $-0.02 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $242.1M |
| Total DebtLower is stronger | $90.3M | $428.4M |
| Stockholders' EquityBook value | $778.2M | $27.0M |
| Total Assets | $1.1B | $813.8M |
| Debt / EquityLower = less leverage | 0.12× | 15.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $242.1M | ||
| Q3 25 | $70.5M | $182.7M | ||
| Q2 25 | $90.3M | $136.3M | ||
| Q1 25 | $97.0M | $94.5M | ||
| Q4 24 | $107.7M | $89.5M | ||
| Q3 24 | $89.0M | $98.4M | ||
| Q2 24 | $92.2M | $73.9M | ||
| Q1 24 | $75.8M | $41.9M |
| Q4 25 | $90.3M | $428.4M | ||
| Q3 25 | $93.4M | $429.3M | ||
| Q2 25 | $95.7M | $430.2M | ||
| Q1 25 | $98.0M | $431.1M | ||
| Q4 24 | $125.3M | $432.0M | ||
| Q3 24 | $152.6M | $432.9M | ||
| Q2 24 | $164.9M | $433.8M | ||
| Q1 24 | $167.2M | $384.0M |
| Q4 25 | $778.2M | $27.0M | ||
| Q3 25 | $778.0M | $-7.4M | ||
| Q2 25 | $776.3M | $-12.3M | ||
| Q1 25 | $839.4M | $-28.3M | ||
| Q4 24 | $828.5M | $-27.6M | ||
| Q3 24 | $1.2B | $-31.9M | ||
| Q2 24 | $1.2B | $-28.5M | ||
| Q1 24 | $1.2B | $-26.4M |
| Q4 25 | $1.1B | $813.8M | ||
| Q3 25 | $1.1B | $685.9M | ||
| Q2 25 | $1.0B | $636.9M | ||
| Q1 25 | $1.1B | $579.8M | ||
| Q4 24 | $1.2B | $612.7M | ||
| Q3 24 | $1.7B | $575.0M | ||
| Q2 24 | $1.7B | $543.9M | ||
| Q1 24 | $1.7B | $497.3M |
| Q4 25 | 0.12× | 15.87× | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $183.5M |
| Free Cash FlowOCF − Capex | $21.3M | $175.0M |
| FCF MarginFCF / Revenue | 11.8% | 98.8% |
| Capex IntensityCapex / Revenue | 3.8% | 4.8% |
| Cash ConversionOCF / Net Profit | — | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $326.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $183.5M | ||
| Q3 25 | $14.0M | $79.8M | ||
| Q2 25 | $6.8M | $42.0M | ||
| Q1 25 | $25.7M | $33.3M | ||
| Q4 24 | $57.9M | $148.8M | ||
| Q3 24 | $23.0M | $69.0M | ||
| Q2 24 | $27.8M | $17.5M | ||
| Q1 24 | $-8.0M | $24.2M |
| Q4 25 | $21.3M | $175.0M | ||
| Q3 25 | $7.0M | $78.3M | ||
| Q2 25 | $-4.2M | $40.8M | ||
| Q1 25 | $19.0M | $32.1M | ||
| Q4 24 | $53.1M | $132.0M | ||
| Q3 24 | $20.0M | $62.2M | ||
| Q2 24 | $21.9M | $12.8M | ||
| Q1 24 | $-12.1M | $20.0M |
| Q4 25 | 11.8% | 98.8% | ||
| Q3 25 | 3.9% | 58.0% | ||
| Q2 25 | -2.4% | 34.1% | ||
| Q1 25 | 11.3% | 25.5% | ||
| Q4 24 | 29.6% | 79.9% | ||
| Q3 24 | 11.7% | 50.6% | ||
| Q2 24 | 12.8% | 10.9% | ||
| Q1 24 | -7.3% | 18.4% |
| Q4 25 | 3.8% | 4.8% | ||
| Q3 25 | 3.9% | 1.1% | ||
| Q2 25 | 6.3% | 1.0% | ||
| Q1 25 | 4.0% | 0.9% | ||
| Q4 24 | 2.7% | 10.1% | ||
| Q3 24 | 1.8% | 5.5% | ||
| Q2 24 | 3.4% | 4.0% | ||
| Q1 24 | 2.5% | 3.9% |
| Q4 25 | — | 3.16× | ||
| Q3 25 | — | 7.61× | ||
| Q2 25 | — | 2.72× | ||
| Q1 25 | 3.89× | 71.84× | ||
| Q4 24 | — | 19.54× | ||
| Q3 24 | 5.35× | 16.60× | ||
| Q2 24 | 15.44× | 3.64× | ||
| Q1 24 | — | 11.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
